VF
ARQT icon

Virtu Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Virtu Financial’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,050
Closed -$449K – 1586
2026
Q1 		$449K Buy
+19,050
New +$486K 0.02% 614
2025
Q2 		– Sell
-68,261
Closed -$1.07M – 1433
2025
Q1 		$1.07M Buy
+68,261
New +$962K 0.06% 264
2023
Q3 		– Sell
-21,769
Closed -$207K – 1278
2023
Q2 		$207K Buy
+21,769
New +$242K 0.02% 793

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Virtu Financial's ARQT Position: Q2 2026 in Review

Virtu Financial sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 19,050 shares — an estimated $449K sold.

Virtu Financial first reported a position in ARQT in Q2 2023 and held it in 3 quarters. The position peaked at $1.07M in Q1 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Virtu Financial reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 19,050 Arcutis Biotherapeutics shares in Q2 2026, an estimated $449K.
  • Virtu Financial first reported a position in Arcutis Biotherapeutics in Q2 2023 and held it in 3 quarters.
  • Virtu Financial's Arcutis Biotherapeutics position peaked at $1.07M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.